These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 2751430)

  • 1. [Immunological studies on chronic active Epstein-Barr virus infection in children--low spontaneous cytotoxicity and lymphokine augmented spontaneous cytotoxicity against Raji cells].
    Wakiguchi H; Fujieda M; Matsumoto K; Kurashige T
    Arerugi; 1989 Feb; 38(2):98-103. PubMed ID: 2751430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysis of human solid tumor cells by lymphokine-activated natural killer cells.
    Itoh K; Tilden AB; Balch CM
    J Immunol; 1986 May; 136(10):3910-5. PubMed ID: 3084648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defective generation of killer cells against spontaneously Epstein-Barr virus (EBV)-transformed autologous B cells in a fatal EBV infection.
    Yanagisawa M; Kato M; Ikeno K; Kobayashi T; Miyagawa Y; Komiyama A; Akabane T
    Clin Exp Immunol; 1987 May; 68(2):251-8. PubMed ID: 2820633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Augmentation by anti-T3 antibody of the lymphokine-activated killer cell-mediated cytotoxicity.
    Ting CC; Hargrove ME; Yun YS
    J Immunol; 1988 Aug; 141(3):741-8. PubMed ID: 3260909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ; Krosnick JA; Rosenberg SA
    J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer and activated killer activities in chronic liver disease and hepatocellular carcinoma: evidence for a decreased lymphokine-induced activity of effector cells.
    Hirofuji H; Kakumu S; Fuji A; Ohtani Y; Murase K; Tahara H
    Clin Exp Immunol; 1987 May; 68(2):348-56. PubMed ID: 2820634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defective killer cell activity in patients with chronic active Epstein-Barr virus infection.
    Wakiguchi H; Fujieda M; Matsumoto K; Ohara Y; Wakiguchi A; Kurashige T
    Acta Med Okayama; 1988 Jun; 42(3):137-42. PubMed ID: 2840801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mode of in vitro augmentation of natural killer cell activity by recombinant human interleukin 2: a comparative study of Leu-11+ and Leu-11- cell populations in cord blood and adult peripheral blood.
    Seki H; Ueno Y; Taga K; Matsuda A; Miyawaki T; Taniguchi N
    J Immunol; 1985 Oct; 135(4):2351-6. PubMed ID: 3928745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of systemic recombinant interleukin-2 on natural killer and lymphokine activated killer activity of human tumor infiltrating lymphocytes.
    Anderson TM; Ibayashi Y; Tokuda Y; Colquhoun SD; Holmes EC; Golub SH
    Cancer Res; 1988 Mar; 48(5):1180-3. PubMed ID: 3257716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of natural killer cytotoxicity by recombinant alpha interferons. Augmentation by IFN-alpha 7, an interferon similar to IFN-alpha J.
    Platsoucas CD; Fox FE; Oleszak E; Fong K; Nanno M; Ioannides CG; Trotta PP
    Anticancer Res; 1989; 9(4):849-58. PubMed ID: 2817813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiation of the cytolytic activity of peripheral blood monocytes by lymphokines and interferon.
    Fischer DG; Golightly MG; Koren HS
    J Immunol; 1983 Mar; 130(3):1220-5. PubMed ID: 6401781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens.
    Lanier LL; Benike CJ; Phillips JH; Engleman EG
    J Immunol; 1985 Feb; 134(2):794-801. PubMed ID: 3871216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural killer (NK) cell activity of women with gross cystic disease is inhibited in vitro by breast cyst fluid.
    Ardizzoja M; Masera RG; Tacconis P; Sartori ML; Arisio R; Massobrio M; Angeli A
    Anticancer Res; 1994; 14(2A):555-9. PubMed ID: 8017860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The functional activity of the natural killers in patients with infectious mononucleosis and other viral infections].
    Zverkova AS; Faktorova EI
    Vrach Delo; 1990 Jun; (6):107-10. PubMed ID: 2399702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A study on hematological and immunological disorders in 2 cases with chronic active Epstein-Barr virus infection in childhood].
    Tomoda T; Wakiguchi H; Hamada F; Fujieda M; Ohhara Y; Ogura H; Kurashige T; Kitamura I
    Rinsho Ketsueki; 1987 Aug; 28(8):1394-402. PubMed ID: 3501486
    [No Abstract]   [Full Text] [Related]  

  • 17. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
    Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
    J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of various interferons on the spontaneous cytotoxicity exerted by lymphocytes from normal and tumor-bearing patients.
    Lucero MA; Fridman WH; Provost MA; Billardon C; Pouillart P; Dumont J; Falcoff E
    Cancer Res; 1981 Jan; 41(1):294-9. PubMed ID: 6160906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and immunological considerations in Epstein-Barr virus-associated diseases.
    Andersson J
    Scand J Infect Dis Suppl; 1996; 100():72-82. PubMed ID: 8860357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.